Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Laetitia C Schwab, Shaady N Garas, Janelle Drouin-Ouellet, Sarah L Mason, Simon R Stott & Roger A Barker. (2015) Dopamine and Huntington’s disease. Expert Review of Neurotherapeutics 15:4, pages 445-458.
Read now
Read now
Articles from other publishers (24)
Muath Suliman, Sulieman Ibraheem Shelash Al-Hawary, F. Al-dolaimy, Ahmed Hjazi, Sami G. Almalk, Adnan Taan Alkhafaji, Ahmed Hussien Alawadi, Ali Alsaalamy, Sheela Bijlwan & Yasser Fakri Mustafa. (2023) Inflammatory diseases: function of LncRNAs in their emergence and the role of mesenchymal stem cell secretome in their treatment. Pathology - Research and Practice, pages 154758.
Crossref
Crossref
Bimala Malla, Xuanzong Guo, Gökçe Senger, Zoi Chasapopoulou & Ferah Yildirim. (2021) A Systematic Review of Transcriptional Dysregulation in Huntington’s Disease Studied by RNA Sequencing. Frontiers in Genetics 12.
Crossref
Crossref
Horia Paunescu, Lorena Dima, Isabel Ghita, Laurenţiu Coman, Petru Iulian Ifteni, Ion Fulga & Oana Andreia Coman. (2020) A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American Journal of Therapeutics 27:3, pages e249-e269.
Crossref
Crossref
Sunpreet Kaur, Shamsher Singh, Anchal Arora, Parladh Ram, Sachin Kumar, Puneet Kumar & Sara Nidal Abed. 2020. Frontiers in Pharmacology of Neurotransmitters. Frontiers in Pharmacology of Neurotransmitters
241
292
.
Edina Silajdžić & Maria Björkqvist. (2018) A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward. Journal of Huntington's Disease 7:2, pages 109-135.
Crossref
Crossref
Maurice Garret, Zhuowei Du, Marine Chazalon, Yoon H. Cho & Jérôme Baufreton. (2018)
Alteration of
GABA
ergic neurotransmission in Huntington's disease
. CNS Neuroscience & Therapeutics 24:4, pages 292-300.
Crossref
Crossref
Rhia Ghosh & Sarah J. Tabrizi. 2018. Neurogenetics, Part I. Neurogenetics, Part I
255
278
.
Claudia Rangel-Barajas & George V. Rebec. (2016) Dysregulation of Corticostriatal Connectivity in Huntington’s Disease: A Role for Dopamine Modulation. Journal of Huntington's Disease 5:4, pages 303-331.
Crossref
Crossref
M.L. Choi, F. Begeti, J.H. Oh, S.Y. Lee, G.C. O'Keeffe, C.D. Clelland, P. Tyers, Z.H. Cho, Y.B. Kim & R.A. Barker. (2014) Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. Neurobiology of Disease 66, pages 19-27.
Crossref
Crossref
Robert Wyse, Gary Dunbar & Julien Rossignol. (2014) Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases. International Journal of Molecular Sciences 15:2, pages 1719-1745.
Crossref
Crossref
Roger A. Barker & Sarah L. Mason. (2013) Mapping the natural history of Huntington disease. Nature Reviews Neurology 10:1, pages 12-13.
Crossref
Crossref
. 2013. Metal-based Neurodegeneration. Metal-based Neurodegeneration
337
394
.
Shermali Gunawardena. (2013) Nanoparticles in the Brain: A Potential Therapeutic System Targeted to an Early Defect Observed in Many Neurodegenerative Diseases. Pharmaceutical Research 30:10, pages 2459-2474.
Crossref
Crossref
A. Jahanshahi, R. Vlamings, W.M.C. van Roon-Mom, R.L.M. Faull, H.J. Waldvogel, M.L.F. Janssen, Y. Yakkioui, D.H. Zeef, E. Kocabicak, H.W.M. Steinbusch & Y. Temel. (2013) Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington’s disease. Neuroscience 238, pages 71-81.
Crossref
Crossref
R MacLeod, A Tibben, M Frontali, G Evers‐Kiebooms, A Jones, A Martinez‐Descales & RA Roos. (2013) Recommendations for the predictive genetic test in Huntington's disease. Clinical Genetics 83:3, pages 221-231.
Crossref
Crossref
Rhia Ghosh & Sarah J. Tabrizi. 2015. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease
3
31
.
Rinske Vlamings, Dagmar H. Zeef, Marcus L. F. Janssen, Mayke Oosterloo, Frederic Schaper, Ali Jahanshahi & Yasin Temel. (2012) Lessons Learned from the Transgenic Huntington's Disease Rats. Neural Plasticity 2012, pages 1-8.
Crossref
Crossref
Puneet Kumar, Harikesh Kalonia & Anil Kumar. (2010) Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington’s-like symptoms: a comparative study. Journal of Psychopharmacology 25:10, pages 1399-1411.
Crossref
Crossref
Jess Nithianantharajah & Anthony J. Hannan. (2011) Mechanisms mediating brain and cognitive reserve: Experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:2, pages 331-339.
Crossref
Crossref
Christopher A Ross & Sarah J Tabrizi. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. The Lancet Neurology 10:1, pages 83-98.
Crossref
Crossref
Marianne J.U. Novak & Sarah J. Tabrizi. 2011. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia. Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia
297
323
.
Megan J. Dowie, Emma L. Scotter, Emanuela Molinari & Michelle Glass. (2010) The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacology & Therapeutics 128:2, pages 305-323.
Crossref
Crossref
Ali Jahanshahi, Rinske Vlamings, Ahmet Hilmi Kaya, Lee Wei Lim, Marcus L.F. Janssen, Sonny Tan, Veerle Visser-Vandewalle, Harry W.M. Steinbusch & Yasin Temel. (2010) Hyperdopaminergic Status in Experimental Huntington Disease. Journal of Neuropathology & Experimental Neurology 69:9, pages 910-917.
Crossref
Crossref
Lan Nguyen, John L. Bradshaw, Julie C. Stout, Rodney J. Croft & Nellie Georgiou-Karistianis. (2010) Electrophysiological measures as potential biomarkers in Huntington's disease: Review and future directions. Brain Research Reviews 64:1, pages 177-194.
Crossref
Crossref